Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction
about
Deep Response in Multiple Myeloma: A Critical ReviewNew criteria for response assessment: role of minimal residual disease in multiple myelomaTowards Stratified Medicine in Plasma Cell MyelomaAdvances in understanding prognosis in myeloma.Differentiation stage of myeloma plasma cells: biological and clinical significance.Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life studyMinimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study.Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.Posttransplant maintenance therapy in multiple myeloma: the changing landscape.Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents.Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical TrialsCurrent Review on High-Risk Multiple Myeloma.Multiple Myeloma Minimal Residual Disease.Transplantation for Multiple Myeloma.A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.Standardisation of minimal residual disease in multiple myeloma.Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysisAssessment of minimal residual disease in myeloma and the need for a consensus approach.Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA.Innovations in treatment and response evaluation in multiple myeloma.Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients.CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma.Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation.Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.Guidelines for the use of imaging in the management of patients with myeloma.The effect of novel therapies in high-molecular-risk multiple myeloma.Copper-64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma.High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges.Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms.Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.
P2860
Q26771228-6D5AD4E5-5C64-413D-8AC2-DC619845C21AQ27027512-E4A39B02-39CF-4101-BE0B-8EB35F21CE35Q28074994-791B67EF-7C79-448A-BBCD-2979A6D733B8Q30244061-95FAB68B-7B98-4D45-AE25-6DBEA9B48A36Q33712516-9C8C6AD9-0EB8-49A2-91E9-9E3FFBA13748Q36705534-D58B97C7-8BFA-4D70-AC19-8FB082E8F821Q36750463-E29460F6-591F-4E4D-ABD9-0A52E22DC45AQ37701511-F5AC2410-1864-41E6-980D-4A12C6733F3FQ37737800-E8709223-2B55-4145-A6D7-550584C4B7E3Q38543122-18ED9340-163E-4A49-A0F7-D2A2398FD225Q38740213-7C37DD3E-E1B3-45C6-9274-FA1B35A0C683Q38789282-DF37065F-F6BD-43F4-B588-5E30BDEDCAA5Q38895167-E9EC6825-584B-4DC4-81CF-DBC8BD345240Q38970590-41B90DAC-4C7E-490F-8A26-BF1151F24A29Q38970603-AC9C5356-1A28-4DBD-9D2A-D139EE3EAF1DQ39112978-8D1CACED-1B4C-4E3F-A62A-B3D46FAC772BQ39386287-4419DAF1-0CCF-4B74-89D3-2AB6807F3F2CQ39410899-426810C4-D11D-49CF-B7E1-DDFE30027755Q40469944-BE2D3996-1C1D-450B-AA18-7BD226B3142DQ40594905-8EDFD105-FC6B-43C5-B1AA-2D4A2287437BQ41556524-5FF60DF1-5A1C-4518-B70D-27AE5932A8AAQ41644146-EBB674CB-81EA-4C4B-AFDE-463B6836FA04Q41924881-E0202E1E-77E1-4915-A2D1-E79BEBCE0464Q42050819-CD07F670-D768-452C-AF60-7BE96E9D5431Q42234608-FCE25F2D-7CD4-4EFA-BFD4-C100EA637CBBQ42399891-32DBF457-DD7F-4775-B056-5FD5560682BFQ42427616-63458908-E98C-4F36-A56B-1E402EE13453Q42715379-8CE689C3-BD04-40AC-AA19-184CD0EC9B08Q46215222-C6D55889-590D-4493-AE78-10734CBBAE1DQ47125786-DA4B1140-448F-433B-9C01-644B59222B1EQ47164979-40F2A345-2CDA-4198-8B45-C88278AA3586Q47230178-6F1611E0-493F-467A-A1EE-0D84C5F7D38BQ47281717-445EA738-D490-404D-B76E-2116CC45774AQ47314920-4727A59E-F6D6-4A83-8B02-384A207512D7Q47329918-8433E24F-9A11-4F89-805E-F19A5289D99FQ47375990-AB792526-907D-472F-84C5-1D0003302980Q47561677-D7F4C60E-9468-4D06-BB80-732E9C1C0FCBQ48268599-BC132BE3-C27A-48BF-88A3-9FCF250E37ECQ50197867-DF5DC452-BA32-472A-BC18-8F49EAA005D2Q50589659-8C85EB69-4D9C-478A-B0D8-B571C9172E6B
P2860
Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Minimal residual disease in my ...... ival benefit per log reduction
@ast
Minimal residual disease in my ...... ival benefit per log reduction
@en
Minimal residual disease in my ...... ival benefit per log reduction
@en-gb
type
label
Minimal residual disease in my ...... ival benefit per log reduction
@ast
Minimal residual disease in my ...... ival benefit per log reduction
@en
Minimal residual disease in my ...... ival benefit per log reduction
@en-gb
prefLabel
Minimal residual disease in my ...... ival benefit per log reduction
@ast
Minimal residual disease in my ...... ival benefit per log reduction
@en
Minimal residual disease in my ...... ival benefit per log reduction
@en-gb
P2093
P2860
P50
P1433
P1476
Minimal residual disease in my ...... ival benefit per log reduction
@en
P2093
Graham H Jackson
J Anthony Child
Roger G Owen
Ruth M de Tute
Sue E Bell
Walter M Gregory
P2860
P304
P356
10.1182/BLOOD-2014-07-590166
P407
P577
2015-02-02T00:00:00Z